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Abstract

Introduction and Aims There has been an increase in prescription of opioids for chronic non‐cancer pain,
and concern exists over possible diversion of prescription opioids to the illicit marketplace. Recent media
coverage suggests that elderly patients sell their prescribed opioids for additional income. This study
investigated the extent to which an Australian community sample of chronic pain patients prescribed opioids
reported supplying their prescribed opioids to others. Design and Methods Participants living with chronic
non‐cancer pain and prescribed opioids for their pain (n = 952) were recruited across Australia via
advertisements at pharmacies. A telephone interview included questions about their pain condition and
opioid medication. Results Participants had been living with pain for a mean of 14.2 years; most common
conditions included chronic back/neck problems and arthritis/rheumatism. Around half (43%) were
currently prescribed one opioid, and 55% had been prescribed 2-5 opioids; the most common was
oxycodone. Forty‐two participants (4%) reported ever supplying prescribed opioids to another person; one
participant reported receiving payment. Participants who supplied opioids to others were younger (odds ratio
0.97, 95% confidence interval 0.95-0.99) and engaged in a greater number of aberrant behaviours relating to
their opioid medication (odds ratio 1.77, 95% confidence interval 1.45-2.17), including tampering with doses,
taking opioids by alternative routes, seeing doctors to obtain extra opioids and refilling prescriptions early.
Discussion and Conclusion Few people with chronic non‐cancer pain divert their opioids to others. Media
reports of elderly patients selling their opioids to supplement their income may be reflective of exceptional
cases. Future studies may investigate the extent to which other patient groups divert prescription opioids to
the illicit marketplace.
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Abstract
Introduction and aims: There has been an increase in prescription of opioids for chronic
non‐cancer pain, and concern exists over possible diversion of prescription opioids to the
illicit market place. Recent media coverage suggests that elderly patients sell their
prescribed opioids for additional income. This study investigated the extent to which an
Australian community sample of chronic pain patients prescribed opioids reported supplying
their prescribed opioids to others.
Design and methods: Participants living with chronic non‐cancer pain and prescribed
opioids for their pain (n=952) were recruited across Australia via advertisements at
pharmacies. A telephone interview included questions about their pain condition and opioid
medication.
Results: Participants had been living with pain for a mean of 14.2 years; most common
conditions included chronic back/neck problems and arthritis/rheumatism. Around half
(43%) were currently prescribed one opioid; 55% had been prescribed 2‐5 opioids; the most
common was oxycodone. Forty‐two participants (4%) reported ever supplying prescribed
opioids to another person; one participant reported receiving payment. Participants who
supplied opioids to others were younger (OR 0.97, 95% CI 095‐0.99) and engaged in a
greater number of aberrant behaviours relating to their opioid medication (OR 1.77, 95% CI
1.45‐2.17) including tampering with doses, taking opioids by alternative routes, seeing
doctors to obtain extra opioids and refilling prescriptions early.
Discussion and conclusion: Few people with chronic non‐cancer pain divert their opioids to
others. Media reports of elderly patients selling their opioids to supplement their income
may be reflective of exceptional cases. Future studies may investigate the extent to which
other patient groups divert prescription opioids to the illicit market place.

Introduction
In the past decade there has been an increase in prescribed opioids for chronic non‐cancer
pain,1‐4 with concern over concomitant increases in dependent use and overdose.1 2 5 This
concern has arisen in parallel with concerns about the appropriateness of opioids in the
longer term for the management of chronic non‐cancer pain,6 in contrast to acceptance of
opioids as ‘essential medicines’ for the management of cancer pain.7
Opioids are one of the most frequently borrowed and shared prescription medications8‐10.
Research suggests that the majority of people within the general population who borrow
prescription opioids obtain them from a family member or friend.11

14

In an Australian

survey of drug treatment clients that reported regular non‐medical pharmaceutical use12
over a third of the sample gave away opioids prescribed for them. Further, among this
sample most pharmaceutical opioids used over the four weeks prior to entry into treatment
were not sourced directly from a prescriber, but were bought from a friend, from the illicit
market, or were a gift from a friend or partner. There has therefore been concern over the
possibility that there is diversion of prescribed opioids from patients to the illicit market,
which may be partially driving extra‐medical use and dependence.13 14
Media coverage suggests elderly patients prescribed opioids for chronic pain sell them to
supplement their income, referred to as “fossil pharming”.15 16 There is limited data on this
issue, and existing data on the extent to which elderly chronic pain patients provide opioids
to others has been mainly qualitative.17 However the possibility that older people are
diverting their opioids to the illicit market is of concern given that, for example, Australian
people aged 60 years and older receive around two thirds of morphine prescriptions, and
three quarters of oxycodone prescriptions.1 To further address this possibility, we
investigated the extent to which people living with chronic pain supplied their prescribed
opioids to others, using data from an Australian community sample.

Methods
The data reported here are from the first 952 participants recruited into the Pain and
Opioids IN Treatment (POINT) cohort (http://ndarc.med.unsw.edu.au/project/point‐study‐
pain‐and‐opioids‐treatment). This study is intended to follow participants at multiple points
over a two year period. The major aims of the study are to examine the natural history of
prescribed opioid use; examine the predictors of adverse events; and identify factors that
predict poor self‐reported pain relief and other outcomes. This study received ethical
approval from the University of New South Wales.
With National Pharmacy Guild approval, we contacted 2,915 pharmacies from a national
database of Australian pharmacies. All Tasmanian pharmacies were sampled first, followed
by a random sample of pharmacies from NSW and then across Australia. Research staff
contacted each selected pharmacy via phone to a) briefly explain the study and b) ask
whether they would help with study recruitment.
Of the pharmacies selected, 1,121 (38%) agreed to help with recruitment. The spread of
pharmacies mirrored the geographic distribution of the Australian population. Pharmacists
that assisted with recruitment asked customers that had been prescribed a schedule 8
opioid (i.e., drugs of dependence that are subject to additional regulatory controls regarding
their manufacture, supply, distribution, possession and use18) if they would be interested in
taking part in a study on pain and opioids. Pharmacists were reimbursed $20 for each
eligible customer that was referred to the study. Interested people were invited to contact,
or send in their contact details to the study team. The research team assessed each
interested person’s eligibility and explained the study in full before gaining voluntary
informed consent to participate. As the current study was part of a large survey
(encompassing the aims outlined in the previous paragraph) participants were not
specifically told that the interview would include questions regarding diversion of their
medication, nor was this the focus of the questions that were asked. It was explained to
participants that their data would be kept confidential and would not be shared with
anyone outside of the research team unless they threatened harm to themselves or others
(as required by university ethics). Participants were given the option to decline to answer
any of the questions throughout the interview.

Eligible participants were those who met the following criteria: a) English speaking, b)
prescribed opioids (e.g., oxycodone) for 6 weeks or more, c) living with chronic pain (defined
as pain for three months or longer), d) no current cancer, and e) not currently undergoing
opioid substitution treatment for the management of opioid dependence developed
through illicit opioid use. Telephone interviews with participants were conducted by trained
interviewers with a minimum of four years undergraduate training in psychology.
Participants were reimbursed for their time ($40).
Questions used in this analysis included demographics such as age, gender and weekly
income, current pain medication, number of opioid medications currently prescribed and
the duration of current opioid treatment episode. Participants were also asked whether
they had ever supplied or offered prescribed opioids to others (yes/no), if so, how
frequently, how long ago, whether they received payment, and to whom they
supplied/offered prescribed opioids.
All participants were asked questions regarding aberrant opioid‐related behaviours over the
past three months, using the Opioid Related Behaviours in Treatment scale (ORBIT)19. The
scale comprises 10 items (e.g., ‘Over the past 3 months, I have asked my doctor for an
increase in my prescribed dose’) and each item was scored dichotomously (yes/no) in the
current study. The ORBIT scale was developed for use among Australian patients receiving
opioid therapy for pain or opioid dependence in both clinical and research settings. The
scale has demonstrated strong internal consistency (Cronbach’s alpha = 0.85).19

Results
Of the 1778 individuals referred to the study by pharmacists, 472 (27%) were ineligible. Of
the remainder, 952 participated (53%, 73% of eligible participants), 228 declined to take
part in the study (13%, 17% of eligible participants), and 106 felt they were too unwell to
take part in the study (6%, 8% of eligible participants). Fifty‐one participants were eligible
but had not completed their baseline interview at the time of this study.
The sample was approximately half male (44.5%) with a mean age of 58 years (range 19‐89).
Participants had been living with chronic pain for a mean of 14.2 years (SD =12.4); just under
three quarters (70.7%, n =296) had two or more current pain conditions. The most common
pain conditions included chronic back or neck problems and arthritis/rheumatism.
Around half the sample were currently prescribed one opioid (n =403), the other half were
prescribed two to five opioids (n =528). The most commonly prescribed opioid was
oxycodone (see Table 1).
Table 1 about here
As observed in Table 2, 42 participants (4%) reported ever supplying/offering prescribed
opioids to another person. Most participants reported doing so on one to 12 occasions, with
median of 2 times, and a median of 6 months ago (range 1–276 months). One participant
supplied prescribed opioids to their partner more than 100 times (no payment). Participants
reported offering prescribed opioids to a partner (n=7), relative or friend (n=21) and three
participants refused to specify. One participant reported receiving payment for supplying
their friend prescribed opioids on four occasions. More than half of the participants who
supplied/offered prescribed opioids (26 of 42 participants) were prescribed oxycodone;
those who supplied/offered others their prescribed opioids were more likely to be currently
prescribed hydromorphone (n=5, 11.9%) than participants who did not report such
behaviour (n=37, 4.1%).
As seen in Table 1, participants who reported supplying/offering prescribed opioids were
significantly younger; only 11 participants over 65 years reported supplying/offering
prescribed opioids to others. Participants who supplied/offered prescribed opioids were no
more likely to be male or female. Further, participants on a lower income (i.e., $0‐399) were

no more likely to have supplied/offered prescribed opioids compared to participants on
higher incomes.
Table 2 about here
As observed in Table 1, the two groups did not differ with regard to the length of time they
had been prescribed opioids. However, participants who reported supplying/offering their
prescribed opioids to others were currently prescribed a significantly greater number of
opioids (M = 2.05, SD = 0.85) than those who did not (M = 1.67, SD = 0.79, OR 1.70, 95% CI
1.20‐2.40).
Participants who supplied/offered opioids also endorsed more aberrant opioid medication
behaviours on the ORBIT scale (M = 1.61, SD = 1.97) compared to participants who did not
(M = 0.53, SD = 0.90; OR 1.77, 95% CI 1.45‐2.17; Table 1). Considering the individual ORBIT
items (Table 3), in comparison with participants who did not report supplying/offering their
prescribed opioids to others, participants who did were significantly more likely to: a) ask
their doctor for an early renewal of their prescription because they had run out early (26%
vs. 10.1%; OR 3.17, 95% CI 1.54‐6.51), b) go to a different doctor to get their opioid
medication without telling their normal doctor (4.8% vs. 0.9%; OR 5.59, 95% CI 1.15‐27.20),
c) alter their dose, e.g. cutting patches or pills in half when not advised to do so (21% vs.4%;
OR 6.21, 95% CI 2.77‐13.89), and d) take their opioids by a different route than prescribed
(e.g. injecting) (9.5% vs. 0.3%; OR 31.58, 95% CI 6.83‐146.09).
Table 3 about here

Discussion
Our study suggests that it is uncommon for people living with chronic pain to sell prescribed
opioids to supplement income, or to offer it to others, and those who do supply/offer opioid
medications to others, do so infrequently. Four percent of participants (42 out of the sample
of 952) had ever engaged in medication sharing, and those that had supplied/offered their
medication reported doing this a median of 2 times in their lifetime. A review of opioid
related diversion suggests that several pathways of prescription opioid diversion exist
including theft, doctor shopping and fraud20. Further, rates of diversion from other sources,
for example college students prescribed opioids for acute pain conditions, have been found
to be as high as 29 percent (50 of 171 participants)21. The smaller number of participants
who diverted within the current study may indicate that other populations could be
providing a larger amount of opioids to the illicit market place and future studies could aim
to further investigate diversion within these groups.
With respect to the suggestion that elderly people may be likely to supply/offer their
prescribed opioids to others, participants who did report such behaviour were significantly
younger compared to those who did not, and only 11 were aged over 65 years. Over half the
participants who reported supplying/offering prescribed opioids were on a lower income,
however this was reflective of the sample as a whole. Only one participant reported
receiving payment for their prescribed opioids. Rather, participants in the current study
typically offered prescribed opioids to a family member or friend. Such findings are
consistent with previous research that suggests the majority of people who borrow
prescription opioids obtain them informally11 12 22.
Participants who reported supplying/offering their prescribed opioids to others endorsed a
significantly greater number of aberrant behaviours, which included early renewal of their
opioid prescriptions, seeking opioids from more than one doctor, tampering with their dose
and taking opioids by a different route than prescribed. It seems that those who are willing
to supply/offer their prescription opioids to others are less likely to follow doctors’
recommendations in general with regards to their medication.
Our study provides a preliminary indication of the characteristics of chronic pain patients
who divert their prescribed opioids. There was a small proportion of participants who

diverted their medication (4%). Although there was no corroborative evidence to indicate
that participants were reporting truthfully about their sharing of prescription opioids, they
were informed that their responses would be de‐identified and confidential; this has
traditionally resulted in valid reports around illicit drug use.

23

Further, participants had

nothing to gain from misrepresenting their behaviours, increasing the reliability of self‐
report in this context.

24

While, there were no consequences to participants for disclosing

diversion activities, it may be that people who engaged in such activities declined to take
part in the study altogether due to fear that their responses may filter back to their
pharmacy or legal authority. The chronic pain population within the current study is similar
in terms of characteristics (i.e., age, gender distribution, length of time prescribed opioids,
number of opioids prescribed) to other studies of chronic non‐cancer pain patients,
suggesting that our sample may not be overly biased in this regard. 25 26
It is possible that the results may have been affected by social desirability bias, whereby
some chronic pain patients were reluctant to report supplying or offering their prescribed
opioid. However, rather than diverting medications for financial gain, it appears most
instances of medication sharing were giving their medication to family members or friends
in an attempt to be helpful, which may not necessarily be perceived as socially undesirable.
Media reports15 16 and previous research4 indicating that elderly people are an important
source of prescription opioids for the illicit market is not consistent with our findings. Our
sample of people who were living with chronic pain did not appear to be engaging in
considerable diversion. This may not be surprising given that they have current pain, and
might be expected to prefer to use opioids to assist with management of this pain. This does
suggest that a more important source of illicit opioids may be from patients who do not
regularly need opioids for pain, or other sources. It seems clear that given the apparent
scale of prescription opioid misuse among illicit drug users in Australia (e.g., 27), that there
must be considerable diversion occurring from other channels. Further research is needed
to understand how prescribed opioids are diverted to the illicit marketplace.
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Table 1: Characteristics of chronic pain participants according to whether they reported
supplying or offering opioids to others

Age in years, mean (SD)
Gender, n (%)
Male
Female
Weekly income, n (%)
$800 or more
$400 ‐ 799
$399 or less
Current prescribed opioids, n (%)
Morphine
Oxycodone
Codeine
Methadone
Buprenorphine
Fentanyl
Tramadol
Hydromorphone
Dextropropoxyphene
Length of time prescribed opioids,
months mean (SD)
Number of current prescribed opioids,
mean (SD)
ORBIT items rated ‘yes’, mean (SD)

Supplied or offered opioids to
others
No
Yes
n = 910
n = 42
58.05 (13.3)
52.48 (14.0)
400 (44.0)
510 (55.9)

23 (54.8)
19 (45.2)

96 (10.5)
221 (24.3)
590 (64.8)

6 (14.3)
9 (21.4)
27 (64.3)

131 (14.4)
472 (51.9)
84 (21.7)
35 (3.8)
211 (23.2)
132 (14.5)
132 (14.5)
37 (4.1)
14 (1.5)
91.78 (99.70)

OR (95% CI)
0.97 (0.95‐0.99)

Total
N = 952
57.81 (13.4)

1.54 (0.83‐2.87)
Ref.

423 (44.5)
529 (55.4)

Ref.

102 (10.7)
230 (24.2)
568 (59.9)

1.19 (0.52‐2.73)
1.51 (0.80‐2.85)
1.64 (0.87‐3.01)
2.63 (0.89‐7.78)
1.18 (0.58‐2.38)
0.80 (0.31‐2.06)
1.18 (0.51‐2.71)
3.12 (1.19‐8.58)*
1.56 (0.20‐12.16)
1.00 (0.99‐1.00)

138 (14.5)
498 (52.3)
304 (31.9)
39 (4.1)
222 (23.3)
137 (14.4)
139 (14.6)
42 (4.4)
15 (1.6)
92.7 (100.2)

1.67 (0.79)

7 (16.7)
26 (61.9)
7 (43.8)
4 (9.5)
11 (26.2)
5 (11.9)
7 (16.7)
5 (11.9)
1 (2.4)
112.99
(110.18)
2.05 (0.85)

1.70 (1.20‐2.40)

1.7 (0.8)

0.53 (0.90)

1.61 (1.97)

1.77 (1.45‐2.17)

0.58 (1.0)

0.97 (.51‐1.86)

Note. $ = AUD; ORBIT = Opioid Related Behaviours in Treatment scale
*
p < 0.05

Table 2: Characteristics of participants who reported supplying/offering their prescription
opioids
Supplied or offered
Number of participants (% of sample)
Median number of occasions (Range)
Median no, months since last supplied/offered (Range)
Number who received money for prescribed opioids (% of total sample)
Relationship, n (% of those who supplied/offered)*
Partner
Family member
Friend or acquaintance
Dealer
Refused
*n=7 missing

42 (4.4)
2 (1 ‐ >100)
6 (1 – 276)
1 (0.1)
7 (21.9)
9 (28.2)
12 (37.5)
0 (0)
3 (6.5)

Table 3: Differences in non‐adherent behaviours according to whether participants had supplied their opioids to others

In the past three months…

Supplied or offered
opioids to others
No
Yes
n = 910
n = 42
n(yes) (%)
n(yes) (%)
188 (20.8)
14 (33.3)
91 (10.1)
11 (26.2)
18 (2.0)
4 (9.5)

OR (95% CI)

1. I have asked my doctor for an increase in my prescribed dose
1.90 (0.98‐3.68)
2. I have asked my doctor for an early renewal of my prescription because I had run out early
3.17 (1.54‐6.51)*
3. I have used another person’s opioid medication, for example a friend, partner or family
5.18 (1.67‐16.04)
member’s medication, or bought it from the street
2.19 (0.89, 5.38)
4. I have saved up my opioid medication, just in case I needed it later
64 (7.1)
6 (14.3)
5. I have gone to a different doctor to get more opioid medication and didn’t tell my normal
8 (0.9)
2 (4.8)
5.59 (1.15‐27.20)*
doctor about it
6. I have asked my doctor for another opioid prescription because either I had lost my
38 (4.2)
4 (9.5)
2.40 (0.81‐7.06)
prescription or medication, had had it stolen or someone else had used it
7. I have given or sold my prescription or my prescribed medication to someone else
0 (0.0)
10 (23.8)
N/A
8. I have altered my dose in some other way, for example cutting patches or pills in half, when I
38 (4.2)
9 (21.4)
6.21 (2.77‐13.89)*
was not advised to do so by a healthcare professional
9. I have taken my opioid medication by a different route than was prescribed, for example by
3 (0.3)
4 (9.5)
31.58 (6.83‐
injecting it
146.09)*
32 (3.5)
4 (4.4)
2.87 (0.96‐8.51)
10. I have used my opioid medication for other purposes, for example to help me sleep or to
help with stress or worry (do not count times when you took opioids at bedtime so that you
would not be in pain)
Note. Items refer to the past 3 months
Note. A p‐value of <.005 (.05 divided by 10) was used as the cut‐off for significance as each of the ten items were analysed separately.
* p < .005

Total
N = 952
202 (21.2)
102 (10.7)
22 (2.3)
70 (7.4)
10 (1.1)
42 (4.4)
10 (1.1)
47 (4.9)
7 (0.7)
36 (3.8)

